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Solutions to the discrepancies in the extent of liver damage
following ischemia/reperfusion in standard mouse models
liver ischemia (Fig. 1A and B), indicating that only a small band-
width of ischemia times separates minor I/R injury from maximal
I/R injury. Considering that ischemia intervals of P60 min are
used in the majority of hepatic I/R studies published in the last
5 years (Supplementary Table 1), it should be noted that extend-
ing the ischemia time from 60 to 90 min did not aggravate I/R
injury after 24 h of reperfusion, as both ischemia times produced
a maximum degree of liver damage (Fig. 1A, B, I, and J). Evidently,
there is no gain in using 30 min extra ischemia time with no dif-
ferences in liver damage. A P30 min reduction in ischemia time
can signiﬁcantly decrease the total length of the experiments,
particularly in larger studies. More importantly, performing stud-
ies on livers that are >75% necrotic is unsuitable for two reasons.
Firstly, such damage proﬁles are not clinically representative,
given that peak postoperative ALT values in patients subjected to
I/R rarely exceed ±1000–1500 U/L [5,6]; i.e., >10-fold lower than
in most mouse models (Fig. 1A–D). Given this discrepancy
between mouse models and the clinical situation, we strongly
support the bench-to-bedside-to-bench approach recently
reported by Hou et al. [2] where applicable, whereby experimen-
tal hypotheses and/or results are validated on/with patient mate-
rial obtained in a trial with minimal patient burden. Such an
approach could prevent unnecessary animal experiments and
gauge the clinical relevance and, by extension, the therapeutic
potential of a novel intervention modality. Better alignment of
preclinical research with the clinical situation is crucial to expe-
dite the clinical implementation of new treatments for hepatic I/R
injury, which has proven problematic hitherto.
Secondly, the (patho)physiological mechanisms in considerably
damaged livers may differ from that in livers that are less exten-
sively injured by I/R (i.e., in a clinically more representative
model). This could be attributed to e.g., the allocation of residual
intracellular energy by cells towards survival mechanisms (in
case of moderate hepatocellular damage) versus cell death path-
ways (in case of damage beyond repair), which in turn dictates
the type of cell death (e.g., necrosis, autophagy) and the severity
of the consequent immunological responses [7]. In light of these
differences in pathophysiology, the steep slopes of the ALT ver-
sus ischemia time graphs (Fig. 1A and B, linear segments) imply
that even slight experimental variations have a disproportionally
large effect on the type and extent of liver injury. As it is impos-
sible to eliminate differences between laboratories altogether, it
is recommended to test novel hypotheses or interventions in
mild and severe mouse liver I/R models. Reporting results gener-
ated with different experimental regimens per research group
circumvents the aforementioned comparability issues and auto-
matically beneﬁts the external validity of published liver I/R
data.
Letters to the EditorTo the Editor:
Due to their experimental versatility, mouse models are com-
monly used to study hepatic ischemia/reperfusion (I/R) injury
in relation to (I) the efﬁcacy of surgical interventions [1], (II)
the pathophysiological role of biomolecules [2] as well as cells
[3], and (III) the interplay with parenchymal liver disease [4].
For the assessment of post-ischemic liver damage, plasma ala-
nine transaminase (ALT) and the extent of necrotic cell death,
determined by routine clinical chemistry and histology, respec-
tively, are commonly used as gold standard parameters. A
strong correlation exists between hepatocellular necrosis and
plasma ALT levels (Fig. 1K and L). However, during the develop-
ment of an I/R mouse model for pharmacological intervention
studies, we noticed that the reported damage proﬁles vary con-
siderably amongst similar I/R models, even between studies
from groups with extensive expertise in hepatic I/R research
[1,3,4]. This has several important implications for the use of
mouse I/R models for the abovementioned research purposes,
especially for laboratories with limited experience with these
models. Our letter therefore serves to provide empirical evi-
dence for the experimental discrepancies, address their implica-
tions, and furnish recommendations on how to manage the
implications.
The ﬁrst implication is that mouse models should always be
optimized and attuned to the desired set of outcome parameters
per laboratory rather than on the basis of literature. This is sup-
ported by the fact that liver injury parameters (ALT) routinely
vary >10-fold for the same ischemia and reperfusion times
amongst similar mouse models (Fig. 1C and D; Supplementary
Table 1). The observed interstudy differences most likely stem
from variables related to animal selection (e.g., age, weight, or
strain variations), the surgical procedure (e.g., injection or inhala-
tion anesthesia, portal triad clamping technique), and the accli-
matization conditions, all of which vary considerably in hepatic
I/R literature (Supplementary Table 1). Consequently, the dura-
tion of ischemia should always be attuned to the ALT and necrosis
values per model and not dogmatically adopted from literature,
as the full spectrum of experimental details is not always
reported.
In support of this premise, we have proﬁled hepatocellular
damage at 6 h (Fig. 1A; Supplementary Fig. 2) and 24 h of reper-
fusion (Fig. 1B and E–J) as a function of ischemia time, using a
standardized mouse I/R model (technically detailed in the Sup-
plementary material). Our experiments with C57BL/6J mice
revealed a sigmoidal relationship between liver ischemia time
and hepatocellular injury at both 6 h (Fig. 1A) and 24 h (Fig. 1B)
of reperfusion. At 6 h of reperfusion, ALT plasma levels increased
after an ischemic hit of P20 min and peaked after P45 min ofJournal of Hepatology 2015 vol. 62 j 975–989
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In conclusion, hepatic I/R experiments in mice, especially
when diseased livers are concerned [8], are technically very difﬁ-
cult, even when conducted properly. To maximize outcomes with
respect to hepatocellular (patho)physiology, model reproducibil-
ity, and clinical translatability, hepatic I/R models in mice should
be optimized on the basis of experimental data rather than
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Fig. 1. Characterization of mouse models of liver ischemia/reperfusion injury. Plasma ALT levels (mean ± SD) plotted as a function of liver ischemia time, measured
after (A) 6 h or (B) 24 h of reperfusion. Data are obtained from I/R experiments in male C57BL/6J mice subjected to 20–90 min of partial (70%) liver ischemia or a sham
operation (n = 4–13/group, total of 89 animals). The ﬁve-parameter logistic curve ﬁts (black lines) show a goodness-of-ﬁt (R2) of 0.9028 and 0.9051 for the (A) 6-h and (B)
24-h reperfusion ALT data, respectively, which corresponds to a mean half-maximum-effect (logEC50) ischemia time of 34 min. Panels (C) and (D) show the (estimated) ALT
values (y-axis, log2 scale) extracted from all publications reporting the use of a mouse model of hepatic I/R in the last 5 years (see Supplementary Table 1) as a function of
ischemia time (60 and 90 min, x-axis). The ALT values were measured after (C) 6 h or (D) 24 h of reperfusion. Only data from experiments performed with wild type mice
without parenchymal liver disease were used to compile this Figure and Supplementary Table 1. The red dots represent our own data. Panels (E–J) are typical histological
images obtained after 20–90 min of ischemia or sham operation and 24 h of reperfusion. The percentage of conﬂuent parenchymal necrosis and corresponding plasma ALT
levels are shown at the top of each panel. Conﬂuent parenchymal necrosis was scored in a blinded fashion by J.V. using the following scoring system: 0 = 0%, 1 < 25%, 2 = 25–
50%, 3 = 50–75%, 4 > 75%. The values between brackets indicate the range. The duration of ischemia is shown in the bottom right of each panel. Areas of viable hepatocytes
are encircled in white (dashed line). In line with earlier reports [9,10], (morphological) signs of apoptosis were not evident in our experiments. Panels (K) and (L) depict the
correlation between plasma ALT concentrations and the extent of hepatocellular necrosis in our mouse model after 6 h and 24 h reperfusion, respectively. The Spearman
correlation coefﬁcient (r) is shown at the bottom right. Detailed protocols for the abovementioned experiments and an extensive literature overview of mouse hepatic I/R
injury models from the last 5 years are provided in the Supplementary material. (This ﬁgure appears in colour on the web.)
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literature alone. In addition, it is advised to perform studies on
mild and severe mouse models of I/R injury and to validate
results generated with these models on clinical material.
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Hepatic hepcidin expression is decreased in cirrhosis and HCC
To the Editor:
Recent evidence published in this Journal showed the protective
role of the iron homeostasis regulator hepcidin (Hamp) in iron
overload-related liver diseases [1]. The study by Lunova et al. ele-
gantly demonstrated that the knockdown of hepcidin promotes
hepatic inﬂammation and ﬁbrogenesis after feeding mice an
iron-rich diet [1].
It is well known that perturbations of the iron metabolism, as
it is the case in hemochromatosis, can lead to hepatocellular car-
cinoma (HCC). HCC represents the second most common cancer-
related death worldwide and displays also the end-stage of liver
diseases related to chronic viral or non-viral hepatitis.
As hepcidin deﬁcient mice were more prone to develop ﬁbro-
sis [1], which is itself a risk factor for HCC, deregulation of Hamp
might also play a role in the progression of chronic liver disease
to HCC development. Also alcohol intake, another risk factor for
HCC development, lowers hepatic Hamp expression in a murine
model of alcoholic steatohepatitis [2].
Regarding HCC, low Hamp levels have been reported in late
stage murine and rat tumors [3,4]. As this downregulation might
display a late, secondary, rather than an initial effect of carcino-
genesis, we aimed at deciphering whether Hamp expression is
already decreased in early hepatocarcinogenesis. We observed
that mice treated with the carcinogen diethylnitrosamine
(DEN), to induce hepatocarcinogenesis, showed decreased hepa-
tic Hamp expression already in an early stage of tumor develop-
ment (Fig. 1A). Hamp expression was also reduced in tumor
tissues, compared to matched adjacent normal liver tissues, in a
later stage of murine tumorigenesis (Fig. 1B).
To test the relevance of the observed decreased hepcidin in
rodent HCC for human disease, we analyzed a large human Gene
Omnibus (GEO) dataset (GSE14520 [5]), mostly consisting of hep-
atitis B virus (HBV)-related HCC samples. Hamp expression was
strongly decreased in the majority of tumors compared to normal
liver samples (Fig. 1C). This is in line with results from a small
HCC cohort with mixed etiology [6]. Interestingly, serum
hepcidin levels were shown to be decreased in patients with
chronic hepatitis C [7]. To test for hepatic hepcidin expression
in cirrhosis, we analysed two additional datasets containing
cirrhotic liver samples. Cirrhotic tissues showed lower Hamp
expression compared to healthy liver samples in an HBV-related
cohort (Fig. 1D) as well as in HCV-infected patients (Fig. 1E).
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